News coverage about Amgen (NASDAQ:AMGN) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amgen earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 47.0484030070029 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Regeneron CEO: We’re trying to change the paradigm on dru… (finance.yahoo.com)
- Amgen Inc. (AMGN) – Lookout Watch Unusual Volume stock – Wall Street Morning (wallstreetmorning.com)
- Short Interest in Amgen, Inc. (AMGN) Increases By 20.2% (americanbankingnews.com)
- The ODYSSEY Trial Ends Well — But Will It Be Enough? (finance.yahoo.com)
- Regeneron and Sanofi Plan to Cut Cholesterol Drug Price (finance.yahoo.com)
Shares of Amgen (NASDAQ AMGN) traded down $1.80 during trading on Monday, reaching $189.30. The company had a trading volume of 6,970,000 shares, compared to its average volume of 6,690,000. Amgen has a 52 week low of $152.16 and a 52 week high of $201.23. The company has a market capitalization of $136,400.00, a price-to-earnings ratio of 17.21, a PEG ratio of 2.35 and a beta of 1.37. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be paid a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a yield of 2.79%. The ex-dividend date is Wednesday, May 16th. Amgen’s payout ratio is presently 48.00%.
Amgen declared that its Board of Directors has approved a share repurchase plan on Thursday, February 1st that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.
A number of analysts have commented on the company. Leerink Swann restated a “market perform” rating on shares of Amgen in a research report on Friday, February 2nd. Atlantic Securities cut Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price target for the company. in a research report on Monday, February 5th. BidaskClub upgraded Amgen from a “sell” rating to a “hold” rating in a research report on Thursday, January 18th. Oppenheimer set a $205.00 target price on Amgen and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, Credit Suisse Group increased their target price on Amgen from $191.00 to $194.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company. Amgen has a consensus rating of “Hold” and a consensus price target of $191.72.
In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total transaction of $269,665.75. Following the completion of the transaction, the executive vice president now directly owns 56,106 shares of the company’s stock, valued at $9,921,223.98. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders have sold 4,575 shares of company stock valued at $818,361. 0.19% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Amgen (AMGN) Getting Somewhat Positive Media Coverage, Analysis Finds” was originally published by BBNS and is owned by of BBNS. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://baseballnewssource.com/2018/03/12/amgen-amgn-getting-somewhat-positive-media-coverage-analysis-finds/2019910.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.